Risperidone cost study findings disputed

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.463, 2004-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

No cost saving with risperidone

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 247, 2000-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Effectiveness and Cost of Risperidone and Olanzapine for Schizophrenia: A Systematic Review

By Hargreaves William A.  

CNS Drugs, Vol. 19, Iss. 5, 2005-01 ,pp. : 393-410

Adis International

Access to resources Recommend Favorite

Long-acting risperidone cost saving in schizophrenia

By  

Inpharma, Vol. 1, Iss. 1517, 2005-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Long-acting risperidone cost saving in schizophrenia

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 492, 2005-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom: Findings from the INFORCE Study

By Reckless John   Davies Glenn   Tunceli Kaan   Hu X. Henry   Brudi Philippe  

Value in Health, Vol. 13, Iss. 6, 2010-09 ,pp. : 726-734

Blackwell Publishing

Access to resources Recommend Favorite